Reader TTS

In the field of advanced prostate cancer, a number of therapeutic agents are now available. The sequence of administration of medications with distinct mechanisms of action, toxicities and

efficacies, will have a critical role in disease outcomes. The identification of biomarkers predicting response will help to determine the appropriate therapeutic sequence. Access through

your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12

print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be

subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support

REFERENCES * Nadal, R. _ et al_. Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. _Prostate_ 74,

1560–1568 (2014). Article  CAS  Google Scholar  * Schweizer, M. T. _ et al_. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic

castration-resistant prostate cancer. _Eur. Urol._ 66, 646–652 (2014). Article  CAS  Google Scholar  * Azad, A. A. _ et al_. A retrospective, Canadian multi-center study examining the impact

of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. _Prostate_ 74, 1544–1550 (2014). Article  CAS  Google Scholar  *

Sweeney, C. _ et al_. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III

randomized trial [abstract LBA2]. _J. Clin. Oncol._ 32 (Suppl.), 5s (2014). Google Scholar  * Ryan, C. J. _ et al_. Abiraterone in metastatic prostate cancer without previous chemotherapy.

_N. Engl. J. Med._ 368, 138–148 (2013). CAS  Google Scholar  * Beer, T. M. _ et al_. Enzalutamide in metastatic prostate cancer before chemotherapy. _N. Engl. J. Med._ 371, 424–433 (2014).

Article  Google Scholar  * Ryan, C. _ et al_. Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant

prostate cancer (mCRPC) patients (pts) without prior chemotherapy [abstract 7530]. _Ann. Oncol._ 25 (Suppl. 4), iv255–iv279 (2014). Article  Google Scholar  * Antonarakis, E. S. _ et al_.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. _N. Engl. J. Med._ 371, 1028–1038 (2014). Article  Google Scholar  * Suzman, D. L. & Antonarakis, E. S.

Castration-resistant prostate cancer: latest evidence and therapeutic implications. _Ther. Adv. Med. Oncol._ 6, 167–179 (2014). Article  Google Scholar  * Aparicio, A. M. _ et al_.

Platinum-based chemotherapy for variant castrate-resistant prostate cancer. _Clin. Cancer Res._ 19, 3621–3630 (2013). Article  CAS  Google Scholar  Download references AUTHOR INFORMATION

AUTHORS AND AFFILIATIONS * Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, 4233 HWCRC, Detroit, 48201, MI, USA Ulka Vaishampayan Authors * Ulka Vaishampayan View

author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Ulka Vaishampayan. ETHICS DECLARATIONS COMPETING INTERESTS U.V. is a

speaker for Bayer, Janssen and Astellas/Medivation, a consultant for Astellas/Medivation, and has research support from Astellas/Medivation. RIGHTS AND PERMISSIONS Reprints and permissions

ABOUT THIS ARTICLE CITE THIS ARTICLE Vaishampayan, U. Clinical implications of therapeutic sequence in mCRPC. _Nat Rev Urol_ 12, 13–14 (2015). https://doi.org/10.1038/nrurol.2014.308

Download citation * Published: 18 November 2014 * Issue Date: January 2015 * DOI: https://doi.org/10.1038/nrurol.2014.308 SHARE THIS ARTICLE Anyone you share the following link with will be

able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative